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Different therapeutic strategies in metastatic melanoma 
focused on signalling pathways controlling cell prolif-
eration, cell cycle and apoptosis. While TRAIL (TNF-
related apoptosis-inducing ligand) has been shown to 
be an interesting candidate for inducing apoptosis in 
cancer cells without affecting normal cells, the ability 
of cancer cells to develop resistance, limits its thera-
peutic potential. Using a recently established experi-
mental A-375 melanoma cell model for investigating 
TRAIL resistance, we could demonstrate that the 
aurora kinase A inhibitor Alisertib (MLN 8237) en-
hances the proapoptotic effects of TRAIL and sensi-
tizes TRAIL-selected melanoma cells with acquired 
resistance, associated with an activation of intrinsic 
mitochondrial apoptotic pathways. In course of this 
activation, an upregulation of p53 in the nuclear frac-
tion was shown. Thus, the aurora kinase A inhibitor 
Alisertib is able to overcome TRAIL-induced resis-
tance in melanoma cells suggesting the combination of 
TRAIL and Alisertib as a promising therapeutic strat-
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Introduction 
 
Therapy of metastatic melanoma is still a challenge 
because of its high resistance against traditional che-
motherapeutic drugs as well as against new therapeutic 
approaches. Recently, BRAF inhibitors and immune-
checkpoint modulators have shown promising results 
in melanoma therapy (Shtivelman et al. 2014), how-
ever due to frequent tumor relapse, the development of 
new ideas for improved therapy is still needed. We 
have shown in several experimental models that trig-
gering apoptotic cascades by overexpression of 
proapoptotic factors provides an efficient targeting 
strategy (Bektas et al. 2005, Eberle et al. 2007, Fecker 
et al. 2005, Hossini et al. 2003). Tumor necrosis factor
-related apoptosis-inducing ligand (TRAIL/APO2L) 
belongs to the tumor necrosis factor (TNF) super-
family and binds to its death receptors TRAIL-R1/DR4 
and TRAIL-R2/DR5 (Pan et al. 1997, Walczak et al. 
1997). The particular significance of TRAIL for clini-
cal strategies results from its ability to selectively tar-
get tumor cells, whereas most non-malignant cells are 
largely protected (Yagita et al. 2010). 
 Over recent years, high-throughput analyses 
have provided important insights into molecular path-
ways that play a crucial role in the progression from 
early to advanced melanoma - thereby identifying 
aurora kinases as possible key regulators. Aurora 
kinases are members of a serine/threonine kinase fam-
ily, which are essential for cell division and are there-
fore potential targets for cancer therapy. It was shown 
that aurora kinases are upregulated to high levels dur-
ing melanoma progression from in situ to primary and 
metastatic melanoma (Jeng et al. 2004, Liu et al. 2013, 
Wang et al. 2010). 
 Systemic treatment of human melanoma xeno-
grafts with an aurora kinase small-molecule inhibitor 
or with aurora kinase targeting vectors impairs cell 
proliferation and cell cycle progression and induces 
apoptosis (Wang et al. 2010). Recently, it was shown 
in a mouse xenograft model for metastatic melanoma 
that inhibition of aurora kinase A by Alisertib impairs 
mitosis, induces senescence and markedly blocks cell 
proliferation (Liu et al. 2013). 
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The aim of the present experimental study was to clar-
ify the role of aurora kinase A for TRAIL-induced 
apoptosis in melanoma. Using an established experi-
mental melanoma cell culture model comparing 
TRAIL-selected A-375 and wild type A-375 cells 
(Kurbanov et al. 2007), we investigated the role of 
aurora kinase A in TRAIL resistance. We demonstrate 
that inhibition of aurora kinase A by the selective in-
hibitor Alisertib not only sensitizes human melanoma 
cells for TRAIL-induced apoptosis but also overcomes 
induced TRAIL resistance. This may indicate a new 
promising strategy in melanoma therapy.  
 
Materials and Methods 
 
Cell culture 
TRAIL-sensitive human melanoma cell lines A-375 
and Mel-HO as well as induced TRAIL-resistant A-
375-TS and intrinsic TRAIL-resistant MeWo were 
investigated. A-375-TS cells have been selected by 
continuous treatment with 5 ng/ml TRAIL (Kurbanov 
et al. 2007, 2010). All cell lines were cultivated at 37°
C, 5% CO2 in DMEM (Dulbecco’s Modified Eagle 
Medium; 4.5 g/l glucose; Invitrogen, Karlsruhe, Ger-
many) supplemented with 10% FCS (fetal calf serum) 
and antibiotics (Biochrom, Berlin, Germany). For se-
lection, A-375-TS cells were continuously kept under 
TRAIL treatment (5 ng/ml). For induction of apop-
tosis, soluble human TRAIL (Alexis, Gruenberg, Ger-
many; 20 ng/ml, 16 - 24 h) was applied. Treatment 
with aurora kinase A inhibitor (Alisertib, MLN 8237, 
Selleckchem, Munich, Germany) was set up 2 h before 
TRAIL, whereas control cells received DMSO 
(Dimethyl sulfoxide). Treatment with QVD-Oph 
(Quinoline-Valine-Aspartic-CH2-O-Phenyl) was set 
up 2 h before Alisertib. 
 
Real-time cell analysis  
For obtaining growth curves, cell confluence was con-
tinuously monitored by real-time cell analysis (RTCA, 
xCELLigence, ACEA Biosciences, San Diego, CA, 
USA). The technique is based on microelectrodes inte-
grated in the bottom of each well of special 96-well E-
plates. The cell index corresponds to electric resis-
tance, which itself is largely proportional to cell den-
sity. 1,250 cells were seeded per microtiter well, and 
treatment started after 24 h. 
 
Quantification of apoptosis, cytotoxicity and cell 
viability 
For quantification of apoptosis, cell cycle analyses 
were carried out after propidium iodide staining 
(Riccardi & Nicoletti 2006). Cells were harvested by 
trypsinization, stained with PBS buffer (phosphate-
buffered saline) containing Triton-X 100, sodium 
citrate and propidium iodide (Sigma, Taufkirchen, 
Germany; 40 µg/ml). After centrifugation, cells were 
washed with PBS and analyzed by flow cytometry in a 
FACS (fluorescence-activated cell sorting analyses) 
Calibur. Cytotoxicity was determined in parallel by 
measuring LDH (lactate dehydrogenase) activity in 
culture fluids applying a cytotoxicity detection assay 
(Roche Diagnostics). 
For quantification of cell viability, trypsinized cells 
were stained with calcein-AM viability dye 
(eBioscience; San Diego, CA; 2.5 µg/ml in PBS, 37°C, 
1 h), washed with PBS and analyzed by flow cytome-
try (Berger et al. 2013). 
 
Mitochondrial membrane potential 
For determination of the mitochondrial membrane po-
t e n t i a l ,  t h e  f l u o r e s c e n t  d y e  T M RM 
(tetramethylrhodamine methyl ester perchlorate) was 
used. Cells were harvested by trypsinization, stained 
with TMRM (Sigma Aldrich, Taufkirchen, Germany; 
1 µM, 20 min; 37°C), washed once with PBS buffer 
and analyzed in PBS by flow cytometry (Berger et al. 
2013). 
 
Western blot analysis 
For Western blotting, total protein extracts were ob-
tained by cell lysis in 150 mM NaCl, 1 mM EDTA 
(ethylenediaminetetraacetate), 2 mM PMSF 
(phenylmethylsulfonylfluoride), 1 mM leupeptin, 1 
mM pepstatin, 0.5% SDS (sodium dodecylsulfate), 
0.5% NP-40 (Nonidet-40), and 10 mM Tris-HCl (Tris
(hydroxymethyl) aminomethane hydrochloride), pH 
7.5. For p53 detection, cytosolic and nuclear cell frac-
tions were separated (Berger et al. 2013). Western 
blotting on nitrocellulose membranes was performed 
as described previously (Eberle et al. 2003). 
 The following primary antibodies were used: 
cleaved caspase-3 (Cell Signaling, 3664, rabbit, 
1:1000), caspase-3 (Cell Signaling, 9662, rabbit, 
1:10,000), caspase-8 (Cell Signaling, 9746, mouse, 
1:1000), caspase-9 (Cell Signaling, 9505, rabbit, 
1:1000), p53 (Santa Cruz, sc-126, mouse, 1:500), p21 
(Santa Cruz, sc-6246, mouse, 1:200), Bax (Santa Cruz, 
sc-20067, mouse, 1:200), Bak (Santa Cruz, sc-832, 
rabbit, 1:200), Bcl-2 (Santa Cruz, sc-509, mouse, 
1:200), Mcl-1 (Santa Cruz, sc-12756, mouse, 1:200), 
AURKA (Leica Biosystems, Newcastle Upon Tyne, 
UK; JLM28, 1:750), GAPDH (Santa Cruz, sc-32233, 
mouse, 1:200) and TATA-box-binding protein 
(Abcam, 1TBP18, mouse, 1:2000). 
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Figure 1. Enhanced TRAIL-induced apoptosis and G2 cell cycle arrest by Alisertib. (a) Expression of aurora kinase A was 
investigated by Western blot analysis in melanoma cell lines A-375, A-375-TS, Mel-HO, Mel-2a, and MeWo and was com-
pared to a positive control (HuT-78, cutaneous lymphoma cell line). (b) Growth curves of A-375 and A-375-TS were deter-
mined by real-time cell analysis after treatment with 200 nM Alisertib (A200), TRAIL and the combination. Cell index corre-
sponds to cell confluence. (c) Cell cycle analyses were performed in A-375, A-375-TS, Mel-HO and MeWo in response to 
increasing concentrations of Alisertib (50 nM – 1000 nM, A50 – A1000) +/- TRAIL. They based on flow cytometry after 
propidium iodide staining and were evaluated for percentages of apoptotic, sub-G1 (sG1) cells, for cell populations in G2 or for 
ratios of cells in G1/G2. (d) Examples of cell cycle analyses are given. At least two independent experiments (each one with 
triplicates) showed highly comparable results. 
Results 
 
For evaluating the significance of aurora kinase inhibi-
tors in melanoma, the effects of the selective aurora 
kinase A inhibitor Alisertib on cell proliferation, apop-
tosis and cell cycle progression were determined in 
TRAIL-sensitive melanoma cell lines A-375 and Mel-
HO as well as in intrinsically TRAIL-resistant MeWo. 
The ability to overcome inducible resistance to the 
death ligand TRAIL was further evaluated in a TRAIL 
resistance model based on TRAIL-selected A-375-TS 
cells. Melanoma cell lines showed general protein ex-
pression of aurora kinase A, as determined by Western 
blotting (Figure 1a). Whereas the effects of Alisertib 
alone (200 nM) on A-375 growth remained rather lim-
ited, a significant reduction of cell proliferation was 
recorded when it was used in combination with 
TRAIL. This also applied to A-375-TS, which re-
vealed complete resistance to TRAIL single treatment 
(real-time cell analysis, Figure 1b). 
 Inhibition of cell proliferation correlated with 
significant induction of apoptosis by the combination 
Alisertib/TRAIL, as shown in a concentration series by 
cell cycle analysis. Thus, TRAIL-induced apoptosis 
was clearly enhanced in sensitive A-375 and Mel-HO, 
and TRAIL resistance was overcome in TRAIL-
selected A-375-TS (Figure 1c). In contrast, cytotoxic-
ity was not enhanced by the combination treatment vs. 
TRAIL alone, as determined by release of lactate de-
hydrogenase (data not shown). Alisertib also resulted 
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Figure 2. Enhanced TRAIL-induced caspase processing as well as activation of proapoptotic mitochondrial and p53-dependent 
pathways. (a) Expression of regulators of apoptosis pathways and of cell cycle control was investigated by Western blotting in 
A-375 and A-375-TS in response to 200 nM Alisertib (A200) +/- TRAIL. Analyses included effector caspase-3 and initiator 
caspases -8 and -9, pro- and antiapoptotic Bcl-2 proteins (Bcl-2, Mcl-1, Bax, Bak), p53 and its target p21. Glycerin aldehyde 3 
phosphate (GAPDH) served as loading control for total protein extracts. Nuclear extracts were analyzed for nuclear p53, and 
TATA-binding protein was used as control. (b) Activation of proapoptotic mitochondrial pathways was monitored by determi-
nation of the mitochondrial membrane potential (Dym). Histogram examples are given and cell populations with low (L), me-
dium/normal (M) and high (H) Dym are indicated. (c) Cell numbers with different Dym (L/M/H) were evaluated for A-375 and 
A-375-TS in response to treatment with 200 nM Alisertib (A200) +/- TRAIL. Mean values and SDs correspond to three inde-
pendent experiments (each one with triplicate values).  
in dose-dependent G2 cell cycle arrest in all cell lines, 
which was most pronounced at higher concentrations, 
when almost no G1 cells remained. In contrast, intrin-
sically TRAIL-resistant MeWo could not be sensitized 
for TRAIL, but this cell line was also clearly respon-
sive as seen by massive G2 cell cycle arrest after treat-
ment with 1000 nM Alisertib (Figure 1c, d). 
 To investigate the mechanisms of apoptosis 
induction in more detail, activation of the caspase cas-
cade was examined by Western blotting. Caspase 3 
processing due to TRAIL was largely blocked in A-
375 and was completely blocked in A-375-TS at its 
premature cleavage product of 20 kDa. This blockage 
was decisively overcome in both cell lines by the com-
bination of TRAIL and Alisertib, resulting in mature 
caspase-3 cleavage products of 17 and 15 kDa. It fur-
ther correlated with significant degradation of the cas-
pase-3 proform. Similarly, initiator caspases -8 and -9 
were activated (processed) in A-375 (Figure 2a). 
 No characteristic regulation of antiapoptotic 
(Bcl-2, Mcl-1) or of the two multidomain proapoptotic 
Bcl-2 proteins (Bax, Bak) was observed in course of 
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Figure 3. Enhancement of TRAIL-induced apoptosis by Alisertib depends on caspase activity in contrast to the effects of Alis-
ertib alone. (a,b) Dependency of the proapoptotic effects of Alisertib (200 nM) +/- TRAIL on caspase activity was investigated 
in A-375 and A-375-TS cells treated in addition with the pancaspase inhibitor QVD-Oph (dark bars, 1 h pretreatment). (a) cell 
viability as determined by flow cytometry after calcein-AM staining; (b) apoptosis (sub-G1 cells). (c,d) examples of apoptosis 
(c) and cell viability (d) are given for A-375 cells. Two independent experiments (each one with triplicates) showed highly 
comparable results. Abbreviations: sG1, sub-G1 cells; NV, non-viable cells; V, viable cells. 
 
200 nM Alisertib treatment at 24 h. But significant 
activation of the p53 pathway was found. Whereas p53 
and p21 were not upregulated by TRAIL, Alisertib 
resulted in marked upregulation/stabilization of the 
levels of total p53 and its characteristic target p21. By 
examining the subcellular distribution of p53, it was 
furthermore shown that p53 was clearly upregulated by 
Alisertib in nuclear fractions, an essential step in the 
p53 pathway (Figure 2a). 
 Loss of the mitochondrial membrane potential 
(Δψm) indicates an activation of mitochondrial apop-
tosis pathways. As published by our group, TRAIL led 
to mitochondrial membrane potential breakdown in A-
375 whereas A-375-TS was resistant. Alisertib itself 
did not decrease Dym, but resulted in a hyperpolariza-
tion, its role in apoptosis regulation is not clearly de-
fined (Figure 2b). In combination with TRAIL, how-
ever, a dramatic loss of Dym was observed: 71% +/- 
12% and 30% +/- 5% for A-375 and A-375-TS, re-
spectively (Figure 2c). This suggests that the combina-
tion treatment overruled TRAIL resistance by trigger-
ing mitochondrial proapoptotic pathways. While A-
375-TS are resistant to TRAIL-induced mitochondrial 
membrane potential breakdown, Alisertib is able to 
induce its effect also in this cell line. 
 Furthermore, induction of apoptosis and de-
creased cell proliferation correlated with decreased cell 
viability after Alisertib/TRAIL treatment, as shown by 
calcein-AM staining (Figure 3a, light grey bars). The 
role of caspase-dependent pathways was further eluci-
dated by the use of a pan-caspase inhibitor (QVD-
Oph). Thus, QVD-Oph completely abrogated apop-
tosis induced by TRAIL itself, and it prevented the 
enhancing effect of Alisertib on TRAIL-induced apop-
tosis. In contrast, Alisertib-induced apoptosis was not 
blocked upon caspase inhibition, indicating that the 
enhancing effect and direct induction of apoptosis by 
Alisertib were mediated by distinct mechanisms 
(Figure 3b, c). A similar effect of QVD-Oph was ob-
served on cell viability, namely the loss of cell viabil-
ity due to treatment with TRAIL alone or TRAIL/
Alisertib was prevented (Figure 3a, 3d). This under-
lined the significance of the caspase pathway for apop-
tosis sensitization by Alisertib. 
 
Discussion 
 
The ability of tumor cells to undermine checkpoints of 
cell cycle control results in enhanced cell proliferation 
and induced apoptosis resistance. This understanding 
has led to the identification of new antitumor targets. 
Resistance to TRAIL was related to upregulation of 
Bcl-2 and cIAPs, inhibited Bax activation as well as 
downregulation of death receptors and caspases 
(Eberle et al. 2007, Kurbanov et al. 2007) Aurora 
kinases have come into focus in recent years because 
of their crucial role in cell cycle regulation. Aurora 
kinase A is located at the spindle pole and controls 
transition from G2 phase to mitosis (Andrews et al. 
2003, Vader & Lens 2008). Although constitutively 
expressed in all cells, aurora kinase A was shown to be 
upregulated in a variety of cancer cells (Jeng et al. 
2004).  
 In this study we also demonstrate strong ex-
pression of aurora kinase A in melanoma cells. The 
inhibition of aurora kinase A by the selective inhibitor 
Alisertib was able to overcome inducible TRAIL resis-
tance in melanoma cells, whereas an intrinsically 
TRAIL resistant cell line (MeWo) was not sensitized. 
Indeed, inducible TRAIL resistance, as seen in A-375-
TS, appears as a major problem in melanoma TRAIL 
sensitivity. Thus, we had previously shown expression 
of TRAIL receptor 1 (DR4) in >90% of melanoma 
sections, which is characteristic for intrinsic sensitivity 
and inducible resistance, whereas MeWo is DR4-
negative (Kurbanov et al. 2005).  
 Proapoptotic effects were associated with acti-
vation of the p53/p21 pathway, also seen by nuclear 
accumulation of p53. Interestingly, apoptosis induced 
by Alisertib itself does not enclose activation of the 
proapoptotic caspase cascade nor of mitochondria, 
whereas the combination correlated with activation of 
caspases and loss of mitochondrial membrane poten-
tial. This indicates distinct activities leading to direct 
induction of apoptosis and enhanced TRAIL sensitiv-
ity.  
 A correlation between aurora kinase A overex-
pression and suppression of p53 activity has already 
been discussed previously (Katayama et al. 2004). 
Thus, Aurora kinase A overexpression results in ge-
nomic instability, aneuploidy, cell cycle arrest as well 
as dysregulation of NF-kB and AP-2α, which trigger 
tumor growth, chemotherapy and apoptosis resistance. 
Suppression of p53 eliminates important checkpoints 
in cell cycle and apoptosis control (Meraldi et al. 
2002). It is known that p53 and aurora kinase A are 
involved in a strictly regulated, negative feedback 
loop, which is frequently interrupted in malignant cells 
(Katayama et al. 2004). The important role of p53 for 
epithelial tumors is well described whereas its role in 
melanoma is still controversial.  
 Very recently, Liu and coworkers reported that 
combining aurora kinase inhibitors and TRAIL or 
TRAIL agonistic antibodies triggers apoptosis in mela-
noma cells and melanoma xenografts (Liu et al. 2015). 
In conclusion, both studies using different experimen-
tal models support the strategy to combine aurora 
kinase inhibitors with TRAIL for targeting melanoma. 
28   Journal of Molecular Biochemistry, 2016 
Competing interests 
 
The authors state no conflict of interest.  
 
Authors’ contributions 
 
CI Geilen was involved in project planning, main part 
of experiments, evaluation of the data and writing of 
the paper. M Plötz, SA Quast and K Steinhorst helped 
with experiments while CC Geilen was involved in 
project planning and writing of the paper. J Eberle was 
involved in project planning, evaluation of the data and 
writing of the paper. 
 
Acknowledgements  
 
The study was supported in parts by the German Can-
cer Aid (Deutsche Krebshilfe, Melanomverbund; 10-
8008, TP7). 
 
References 
 
Andrews PD, Knatko E, Moore WJ & Swedlow JR 
2003 Mitotic mechanics: the auroras come into view. 
Curr Opin Cell Biol 15 672-683 
Bektas M, Jolly PS, Müller C, Eberle J, Spiegel S & 
Geilen CC 2005 Sphingosine kinase activity counter-
acts ceramide-mediated cell death in human melanoma 
cells: role of Bcl-2 expression. Oncogene 24 178-187 
Berger A, Quast SA, Plötz M, Kammermeier A & 
Eberle J 2013 Sensitization of melanoma cells for 
TRAIL-induced apoptosis by BMS-345541 correlates 
with altered phosphorylation and activation of Bax. 
Cell Death Dis 4 e477 
Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel 
PT, Orfanos CE & Geilen CC 2003 CD95/Fas signal-
ing in human melanoma cells: conditional expression 
of CD95L/FasL overcomes the intrinsic apoptosis re-
sistance of malignant melanoma and inhibits growth 
and progression of human melanoma xenotransplants. 
Oncogene 22 9131-9141 
Eberle J, Kurbanov BM, Hossini AM, Trefzer U & 
Fecker LF 2007 Overcoming apoptosis deficiency of 
melanoma-hope for new therapeutic approaches. Drug 
Resist Updat 10 218-234 
Fecker LF, Geilen CC, Hossini AM, Schwarz C, 
Fechner H, Bartlett DL, Orfanos CE & Eberle J 2005 
Selective induction of apoptosis in melanoma cells by 
tyrosinase promoter-controlled CD95 ligand overex-
pression. J Invest Dermatol 124 221-228 
Hossini AM, Eberle J, Fecker LF, Orfanos CE & 
Geilen CC 2003 Conditional expression of exogenous 
Bcl-X(S) triggers apoptosis in human melanoma cells 
in vitro and delays growth of melanoma xenografts. 
FEBS Lett 553 250-256 
Jeng YM, Peng SY, Lin CY & Hsu HC 2004 Overex-
pression and amplification of Aurora-A in hepatocellu-
lar carcinoma. Clin Cancer Res 10 2065-2071 
Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk 
J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA & 
Sen S 2004 Phosphorylisation by aurora kinase A in-
duces MDM2-mediated destabilization and inhibition 
of p53. Nat Genet 36 35-62 
Kurbanov BM,Geilen CC, Fecker LF, Orfanos CE & 
Eberle J 2005 Efficient TRAIL-R1/DR4-mediated 
apoptosis in melanoma cells by tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL). J Invest 
Dermatol 125 1010-1019 
Kurbanov BM, Fecker LF, Geilen CC, Sterry W & 
Eberle J 2007 Resistance of melanoma cells to TRAIL 
does not result from upregulation of antiapoptotic pro-
teins by NF-kappaB but is related to downregulation of 
initiator caspases and DR4. Oncogene 26 3364-3377 
Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, 
Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri 
KI, Ecsedy JA, Sosman JA, Kelley MC & Richmond 
A 2013 Targeting aurora kinases limits tumour growth 
through DNA damage-mediated senescence and block-
ade of NF-κB impairs this drug-induced senescence. 
EMBO Mol Med 5 149-166 
Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, 
Ecsedy JA, Sosman JA, Kelley MC & Richmond A 
2015 Combining an Aurora kinase inhibitor and a 
death receptor ligand/agonist antibody triggers apop-
tosis in melanoma cells and prevents tumor growth in 
preclinical mouse models. Clin Cancer Res 21 5338-
5348 
Meraldi P, Honda R & Nigg EA 2002 Aurora-A over-
expression reveals tetraploidization as a major route to 
centrosome amplification in p53-/- cells. EMBO J 21 
483-492 
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner 
R, Ni J & Dixit VM 1997 The receptor for the cyto-
toxic ligand TRAIL. Science 276 111-113 
Quast SA, Berger A, Plötz M & Eberle J 2014 Sensiti-
zation of melanoma cells for TRAIL-induced apop-
tosis by activation of mitochondrial pathways via Bax. 
Eur J Cell Biol 93 42-48 
Riccardi C & Nicoletti I 2006 Analysis of apoptosis by 
propidium iodide staining and flow cytometry. Nat 
Protoc 1 1458-1461 
Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, 
Oren M, Flaherty KT & Fisher DE 2014 Pathways and 
therapeutic targets in melanoma. Oncotarget 5 1701-
1752 
Vader G & Lens SM 2008 The Aurora kinase family 
in cell division and cancer. Biochim Biophys Acta 1786 
60-72 
Journal of Molecular Biochemistry, 2016   29 
Walczak H, Degli-Esposti MA, Johnson RS, Smolak 
PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, 
Schooley KA, Smith CA, Goodwin RG & Rauch CT 
1997 TRAIL-R2: a novel apoptosis-mediating receptor 
for TRAIL. EMBO J 16 5386-5397 
Wang X, Moschos SJ & Becker D 2010 Functional 
analysis and molecular targeting of aurora kinases A 
and B in advanced melanoma. Genes Cancer 1 952-
963 
Yagita H, Takeda K, Hayakawa Y, Smyth MJ & Oku-
mura K 2010 TRAIL and its receptors as targets for 
cancer therapy. Cancer Sci 95 777-783 
30   Journal of Molecular Biochemistry, 2016   
